SUPN:NSD-Supernus Pharmaceuticals Inc.

EQUITY | Drug Manufacturers | NASDAQ Global Market

Last Closing Price

USD 38.45

Change

+0.35 (+0.92)%

Market Cap

USD 1.97B

Volume

0.35M

Yahoo Analyst Target

USD 50.63 (31.68%)

STA Analyst Target

USD 50.92 (32.42%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-02-22 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
WBA Walgreens Boots Alliance Inc.

+0.04 (+0.06%)

USD 69.02B
MYL Mylan N.V.

+0.07 (+0.17%)

USD 22.14B
NBIX Neurocrine Biosciences Inc.

+0.58 (+0.68%)

USD 7.63B
HCM Hutchison China MediTech Limit..

+1.20 (+3.66%)

USD 4.52B
AKRX Akorn Inc.

-0.65 (-2.07%)

USD 3.84B
GWPH GW Pharmaceuticals Plc

-15.06 (-11.38%)

USD 2.98B
HZNP Horizon Pharma plc

-0.13 (-0.92%)

USD 2.29B
IRWD Ironwood Pharmaceuticals Inc.

+0.28 (+1.92%)

USD 2.22B
MDCO The Medicines Company

-1.79 (-5.66%)

USD 2.17B
AERI Aerie Pharmaceuticals Inc.

+0.05 (+0.10%)

USD 2.06B

ETFs Containing SUPN

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.51% 45% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.51% 44% F 36% F
Trailing 12 Months  
Capital Gain 53.19% 80% B- 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 53.19% 80% B- 87% B+
Trailing 5 Years  
Capital Gain 419.59% 89% B+ 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 419.59% 89% B+ 95% A
Average Annual (5 Year Horizon)  
Capital Gain 58.01% 90% A- 95% A
Dividend Return 58.01% 90% A- 95% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 36.84% 68% D+ 34% F
Risk Adjusted Return 157.48% 100% A+ 97% A+
Market Capitalization 1.05B 87% B+ 80% B-

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 47.30 5% F 16% F
Price/Book Ratio 8.58 22% F 13% F
Price / Cash Flow Ratio 5.66 12% F 19% F
Price/Free Cash Flow Ratio 19.23 14% F 29% F
Management Effectiveness  
Return on Equity 26.37% 87% B+ 89% B+
Return on Invested Capital 36.72% 97% A+ 94% A
Return on Assets 17.00% 96% A 96% A
Debt to Equity Ratio 1.25% 74% C 87% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

SUPN:NSD-Supernus Pharmaceuticals Inc.

EQUITY | Drug Manufacturers | NASDAQ Global Market

Last Closing Price

USD 38.45

Change

+0.35 (+0.92)%

Market Cap

USD 1.97B

Volume

0.35M

Yahoo Analyst Target

USD 50.63 (31.68%)

STA Analyst Target

USD 50.92 (32.42%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-02-22